Onconetix, Inc. ONCO
Biotechnology: Pharmaceutical Preparations · IPO 2022 · data as of November 13, 2026
Onconetix, Inc. (ONCO) is a healthcare company listed in the US with a market value of about $2M. In the twelve months to June 30, 2026 it had revenue of $645824 and net income of -$10M, a net margin of -1578.8%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is value (2/5); the weakest is track record (0/5).
Key numbers: a P/E of 0.0, a 5-year average ROIC of -295%.
About Onconetix
Onconetix is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2022. It was profitable in 0 of the last 5 years in our data. Its share count rose by 25880% over three years (dilution for shareholders).
Score: 1.0 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- Profit margin improving
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 5 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue | $645824 | $815371 | $3M | $58465 | — | — |
| Net income | -$10M | -$14M | -$59M | -$37M | -$13M | -$3M |
| Free cash flow | -$10M | — | -$11M | -$14M | -$9M | -$2M |
| EPS (diluted) | $-17.16 | $-16.56 | $-1823.39 | $-7433.19 | $-3739.97 | $-4283.97 |
| Net margin | -1578.8% | -1721.0% | -2325.2% | -63986.5% | — | — |
| ROIC | — | -89.2% | -308.5% | -840.9% | -47.6% | -186.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
What is Onconetix’s P/E ratio?
About 0.0, based on the last twelve months of diluted earnings per share.
Does Onconetix pay a dividend?
Not currently.
Is Onconetix a good stock to buy?
We do not give buy or sell advice. Onconetix scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.